Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis

• Main Authors: Mahtab Vasigh (Author), Mohammadreza Karoobi (Author), Austin D. Williams (Author), Fasika Molla Abreha (Author), Richard J. Bleicher (Author), Seyed Mostafa Meshkati Yazd (Author), Tahereh Shamsi (Author), Ramesh Omranipour (Author), Ahmad Elahi (Author), David Farhat (Author), Mehran Habibi (Author)
• Format: Book
• Published: Hindawi-Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction. Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancers have the lowest response to neoadjuvant therapy of all subtypes. The role of neoadjuvant endocrine therapy (NET) in clinically node-positive (cN+), HR+, HER2− patients is evaluated in this meta-analysis...